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Abstract
Infectious diseases are the leading cause of morbidity and mortality in the developing world. In
Egypt bacterial diseases constitute a great burden, with several particular bacteria sustaining the
leading role of multiple serious infections. This article addresses profound bacterial agents causing
a wide array of infections including but not limited to pneumonia and meningitis. The epidemiology
of such infectious diseases and the prevalence of Streptococcus pneumoniae, Neisseria meningitidis and
Haemophilus influenzae are reviewed in the context of bacterial meningitis. We address prevalent
serotypes in Egypt, antimicrobial resistance patterns and efficacy of vaccines to emphasize the
importance of periodic surveillance for appropriate preventive and treatment strategies.
Introduction
Emerging infectious diseases will always pose a world
threat because of the continuous battle with pathogens
that undergo antigenic changes to escape our immune sys-
tem, and resist antimicrobial treatment. Communicable
diseases are particularly challenging in developing coun-
tries because of poor-socioeconomic conditions that facil-
itate the spread of the pathogens and the abuse of
antimicrobial therapy that results in emerging antimicro-
bial resistant strains, that are resistant to conventional
antimicrobial treatments and possibly vaccines. This arti-
cle addresses communicable diseases that are either trans-
mitted through airborne mechanisms or contact
including droplets and discharge from nose and throat.
The epidemiology of three bacterial meningitis agents will
be reviewed with emphasis on prevalence, antibiotic
resistance and serotypes, to provide the platform for effec-
tive treatment and vaccine strategies in the region. Strepto-
coccus pneumoniae is a leading causative agent of diverse
infections. In Egypt, it was recently described as the lead-
ing cause of bacterial meningitis [1,2] skewing the epide-
miology from Neisseria meningitidis, which was previously
reported as the major etiological agent [3-6]. Acute respi-
ratory infections caused by S. pneumoniae are frequently
reported, yet more recent data are needed to form a com-
prehensive and updated understanding of serotype distri-
bution and antimicrobial resistance pattern in the region
[1,7]. A few studies addressed pulmonary infection from
S. pneumoniae [8,9], with the majority of the studies
addressing pneumococcal meningitis. Reports on the
serotypes of isolates obtained during the studies of pneu-
mococcal meningitis represent a fraction of all the sero-
types causing different forms of pneumococcal diseases
[7]. Additionally, the prevalent serotype distribution had
shown variation along different studies conducted at dif-
ferent time intervals [7,10,11]. In order to assess effec-
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tively the epidemiology of the diseases for effective
preventive and treatment strategies we need to periodi-
cally reassess the serotype prevalence. Currently the major
serotypes reported in Egypt are {6B,1,19A,23F,6A} which
are inadequately represented in the current 7- and 11-
valent vaccine [2,7] urging the production of an effective
regional vaccine. Additionally, penicillin resistance was
reported by several studies at different time intervals
[1,2,8,9,12], with an increase in the pattern of resistance
over time; in 1993 71% S. pneumoniae were susceptible to
penicillin [8], in 2000 63% of isolates were susceptible to
penicillin [9], in 2004 51% of isolates were susceptible to
penicillin [2], therefore periodic monitoring of the pat-
terns of antimicrobial resistance is necessary to guide
effective treatment [4]. In a study conducted from 1998-
2004, 4% of S. pneumoniae (of 560) isolates conferred
multidrug resistance and 50% of these were characterized
as serotypes 23F, 6B, and 6A, which are the prevalent sero-
types in Egypt [2]. A recent study conducted from 1998-
2003 to identify the antimicrobial susceptibility and sero-
type distribution focused on pneumococcal isolates
obtained from CSF [7]. However, isolates causing differ-
ent forms of pneumococcal diseases other than meningi-
tis were not addressed.
Neisseria meningitidis was for long reported as the leading
cause of bacterial meningitis in Egypt, since the early stud-
ies conducted in 1965-1989 [3,5,13]. Recently it was
described as the second or third leading cause after S.
pneumoniae  [1,2,4]. Earlier studies have reported sero-
group A to be the predominant virulent serogroup
[3,13,14]. However, few studies indicated that serogroups
B [1,2,4] and C are replacing serogroup A [10,15], and this
change in the epidemiology of meningococcal meningitis
can be attributed to the use of the group A polysaccharide
vaccine [16-18]. Unfortunately, case mortality in groups B
and C were reported to be higher than A [3,10]. Sulpha-
resistant N. meningitidis was detected since 1965 [5,6].
Due to the lack of standard criteria to evaluate the antibi-
otic susceptibility of N. meningitidis, isolates are not eval-
uated to determine the resistance in most studies. To the
best of our knowledge, Afif et al., was the only study that
addressed the resistance profile findings in Egypt where
86% of isolates were found resistant to co-trimoxazole
and more than 40% were resistant to penicillin [2]. Most
recently a molecular study investigated culture negative
CSF specimens from meningitis patients to rigorously
identify prevalent etiological agent, they reported an
increase in detection rate of N. meningitidis from 16% to
23% making it the second leading cause of bacterial men-
ingitis [2]. It was rationalized that the presence of the high
number of culture negative disease in several studies con-
ducted in Egypt may be due to the uncontrolled use of
antibiotics prior to hospital admission [2,4,6,10,19].
Haemophilus influenzae was less implicated in meningitis
in earlier studies conducted in Egypt [3,13], yet recently it
was reported (serotype b) to be one of the leading causes
of bacterial meningitis in children [1,2,4]. Resistance to
ampicillin, chloramphenicol, ceftriaxone and co-trimoxa-
zole were detected [1,2]. It was reported in several studies
that serotype b is responsible for invasive diseases caused
by H. influenzae [4,5,10]. However, in a study conducted
in 1993 on Egyptian children below 5 years H. influenzae
non-b was found to contribute to 43% of the pneumonia
isolates, questioning the large scale use of Hib vaccine.
Sparse epidemiology studies are available addressing the
role of H. influenzae as a pathogen in Egypt [20].
The epidemiology of bacterial meningitis will be
addressed in the following section by reviewing the prev-
alence of each of these bacteria over 39 years, and address-
ing antimicrobial resistance, serotypes dominance and
vaccine efficacy.
Epidemiology of bacterial meningitis in Egypt
Streptococcus pneumoniae
Streptococcus pneumoniae is known to give rise to several
severe infections. In Egypt it was recently described as the
leading cause of bacterial meningitis [1,2,4] reflecting a
change in the epidemiology of the disease where N. men-
ingitidis was for a long time the main etiological agent
causing bacterial meningitis [3,5,6,13]. Acute respiratory
infections caused by S. pneumoniae require extensive
reporting [1,7,8]. More recent data need to be generated
pertaining to serotype distribution and antimicrobial
resistance patterns, to ensure effective treatment meas-
ures. The following paragraphs address reports on menin-
gitis caused by S. pneumoniae in Egypt.
Pneumococcal meningitis is currently the leading cause of meningitis 
in Egypt
Meningitis caused by S. pneumoniae is often referred to as
pneumococcal meningitis. S. pneumoniae has one of the
highest mortality rates amongst meningitis cases espe-
cially in patients less than one year of age [3,10,13].
Several studies were conducted between 1965 and 2004
on the epidemiology of pneumococcal meningitis, and
revealed a constant rise in the number of S. pneumoniae
meningitis in Egypt. All studies conducted before the mid
1990s demonstrated S. pneumoniae either at second or
third place as the meningitis-causing agent in Egypt
[3,5,6,13]. A longer comprehensive study ES1966-1989 on
7,809 patients admitted to the Abbassia Fever hospital
(AFH), reported that 7.3% of patients that suffered from
meningitis were due to pneumococcal infection and the
peak in the number of cases were during Jan-April. The
mean age of the patients was 11.7 with 41% mortality,Annals of Clinical Microbiology and Antimicrobials 2009, 8:26 http://www.ann-clinmicrob.com/content/8/1/26
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this is five times greater than the mortality caused by N.
meningitidis which was the leading cause of bacterial men-
ingitis during this period. Expectedly, 68% of the mortal-
ity cases reported were less than one year of age [3].
A one year study ES1977-1978 conducted on 1627 CSF spec-
imens obtained from two fever hospitals in Cairo revealed
350 specimens positive for bacterial infection, where
pneumococci were the prevalent bacteria detected com-
promising 8.7% of the total specimens studied (1627)
and 40.6% of bacterial positive specimens (350) with
most cases reported from Jan-May. It is worth noting that
the etiological agent for a large number of the specimens
was not identified. The mortality rate was 44% and again
mortality was mainly reported in patients less than 1 year.
Serotyping by Quellung reaction identified type 1 to be
the most capsular type [10].
In 2000 a project performed by the Ministry of health and
population (MOHP) was carried out in 12 hospitals and
identified S. pneumoniae as the leading cause of bacterial
meningitis. A total of 2455 persons were suspected with
acute meningitis where an overall of 223 had acute bacte-
rial meningitis (ABM). S. pneumoniae was identified in
32% of patients with ABM [1]. Additionally, severe cases,
based on clinical criteria of ABM were highly reported
with  S. pneumoniae, and were the etiological agent of
46.5% of the winter cases [21]. An articulate molecular
study that included 14 hospitals in Egypt to determine the
epidemiology of bacterial meningitis in 11,070 patients
suspected with the disease during ES1998-2004 identified S.
pneumoniae to be the leading cause, responsible for 42%
of the 843 culture-positive bacterial meningitis cases, and
6% of 1,784 culture-negative CSF specimens tested by
PCR. This study by Afifi et. al., used molecular tools to
address the etiological agent of the disease when conven-
tional methods failed. In other studies when culture yields
negative results the disease was described as purulent
meningitis [13], without further investigation of the caus-
ative agent [2]. The high percentage of culture negative
samples was reported in many studies in Egypt. This was
explained by the high frequency of patients receiving on
Percentage of pneumococcal meningitis cases based on studies conducted over 39 years Figure 1
Percentage of pneumococcal meningitis cases based on studies conducted over 39 years. A representation of nine 
different studies conducted on patients diagnosed with meningitis due to different etiological agents from 1965-2004. In the 
study ES1965-1968 on 644 cases of ABM 3% (21 patients) of the cases reported were due to pneumococcal infection [5]. ES1966-
1968 conducted on 187 meningitis patients S. pneumoniae was responsible for 29% of 123 culture-positive cases [6]. ES1966-1989 
conducted on 7,809 meningitis or encephalitis patients, reported that 7.3% of total cases were due to pneumococcal infection 
[3]. A retrospective review ES1971-1975 of 1,333 patients with ABM, reported 7.9% of meningitis cases diagnosed with pneumo-
coccal meningitis [13]. ES1977-1978 revealed pneumococci was the prevalent bacteria detected [10]. Surveillance of 2047 patients 
with meningitis in ES1998-2000 was conducted to determine the etiology of the disease in children less than 6 years. 30% of 228 
patients of the cases confirmed by culture were positive for S. pneumoniae. However, in children older than 12 months and less 
than 6 years, S. pneumoniae was the leading causative agent [4]. ES2000revealed that S. pneumoniae compromised 32% of ABM 
[1]. ES2002-2003 on 310 children clinically diagnosed with meningitis; 202 patients were diagnosed with ABM; 13.9% of total men-
ingitis cases were infected with S. pneumoniae and 21.3% of ABM [21]. ES1998-2004S. pneumoniae was responsible for 42% cul-
ture-positive bacterial meningitis cases [2]. The asterisks represent epidemiological studies reporting an average during the 
entire period of the study.
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the counter antimicrobial drugs prior to professional eval-
uation. [2,4,6,10,19]. Figure 1 summarizes percentage of
pneumococcal meningitis cases based on studies con-
ducted over 39 years.
Antimicrobial resistance and treatment
Extensive studies are required to continually update anti-
microbial susceptibility patterns. In developing countries
the unregulated use of antibiotics is not uncommon,
stressing the importance of surveillance of antibiotic
resistant pathogen to guide empirical treatment. Several
studies reported penicillin resistant S. pneumoniae
[1,2,8,9,12], showing an increase in resistance pattern
over time. Table 1 shows the decrease in the percentage of
penicillin susceptible S. pneumoniae from 1993-2004
[2,8,9]. Such information on patterns of antimicrobial
resistance is an effective mean to guide rational treatment
[4].
One of the initial studies ES1991-1993 that determined the
resistance pattern of S. pneumoniae was conducted in
Abbassia and Embaba fever hospitals. The study involved
1635 children; 961 patients isolates of S. pneumoniae were
recovered from nasopharynx and blood. Table 1 illus-
trates the resistance pattern of the blood isolates tested in
this study, it is important to note that the nasopharyngeal
isolates had similar susceptibility patterns to those of the
blood. The study revealed a low percentage of antimicro-
bial resistance [8]. An increase in penicillin resistance was
recorded in a later study conducted by MOHP where 0.8%
resistance was detected, however all isolates were suscep-
tible to vancomycin [1]. In 1998-2000 the antimicrobial
resistance pattern reported (refer to table 1) recom-
mended ceftriaxone as the drug of choice for treatment of
children with bacterial meningitis [4].
A retrospective multicenter study ES1999-2000 conducted in
5 hospitals in Egypt revealed an increase in penicillin
resistance, and little resistance to Ceftriaxone (84% sus-
ceptible) and Ciprofloxacin (82% susceptible) [9]. A
recent sentinel meningitis surveillance program ES1998-
2003 showed a marked increase in penicillin resistance
(50%-100/205) among CSF isolates in Egypt [7]. Afifi et
al., reported high rates of multidrug resistance in S. pneu-
moniae; 4% of the 206 isolates tested, urging the need to
control the dispensing of antibiotic which are generally
Table 1: Antibiotic resistant S. pneumoniae isolates.
S. pneumoniae PEN OXA CHL CRO TET SXT ERY -Number of isolates tested
-Source
ES 1991-1993
[8]
I = 22.4% NA R = 29.7% NA NA I = 25% I = 0% -47
R = 0% R = 0% R = 0% -Blood
ES 1997-2000
[1]
I = 42% NA I = 0% I = 4% NA NA NA -138
R = 0.8% R = 14% R = 0% -CSF and blood
ES 1998-2000
[4]
I = 52% I = 0% I = 0% I = 0% I = 21% I = 14% NA -29
R = 0% R = 6% R = 2% R = 0% R = 41% R = 2% -CSF
ES 1999-2000
[9]
R = 37% NA R = 18% R = 16% NA R = 37% R = 55% -51
-non-blood
ES 1998-2003
[7]
I+R = NA I+R = I+R = I+R = I+R = I+R = -205
50% 9% 6% 52% 59% 11% -CSF
ES 1998-2004
[2]
I+R = 49 NA I+R = I+R = I+R = I+R = I+R = -206
% 9% 6% 52% 60% 11% -CSF
ES 2003-2005
[12,22]
R = 30% NA NA NA NA NA R = 25% ---------
The percentages of non-susceptible S. pneumoniae isolates to eight conventional antibiotics to S. pneumoniae isolated from CSF and/or blood in eight 
studies conducted from 1991-2004 are summarized.
The percentage of penicillin susceptible S. pneumoniae dropped between 1993-2004; from 71% S. pneumoniae penicillin susceptibility in 1993 [8], 
63% of isolates were susceptible to penicillin in 2000 [9], to 51% penicillin susceptibility in 2004 (2). The study conducted in 1998-2000 
recommended ceftriaxone as the drug of choice for treatment of children with bacterial meningitis [4].
The ES1999-2000study identified resistance to Ceftriaxone (84% susceptible) and Ciprofloxacin (82% susceptible) [9]. ES1998-2004 reported 4% 
multidrug resistance in S. pneumoniae [2]. Additionally, ES 2003-2005reported that 30% penicillin resistance and 25% erythromycin resistance among 
the S. pneumoniae Egypt isolates [12,22].
The antibiotic abbreviations: PEN, penicillin; OXA, oxacillin; CHL, chloramphenicol; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim/
sulfamethoxazole; ERY, erythromycin and NA refers to data not available.
(Intermediate resistance is abbreviated as I, and Resistance as R)Annals of Clinical Microbiology and Antimicrobials 2009, 8:26 http://www.ann-clinmicrob.com/content/8/1/26
Page 5 of 10
(page number not for citation purposes)
available as an over-the-counter medication [2]. Addition-
ally, a surveillance report of the ARMed (Antibiotic Resist-
ance Surveillance & Control in the Mediterranean Region)
project which started in 2003 and continued for 2 years in
the southeastern Mediterranean, reported 30% penicillin
resistance and 25% erythromycin resistance among the S.
pneumoniae Egypt isolates [12,22].
Changes in prevalence serotype
In order to assess the efficacy of vaccine and to provide the
foundations for the development of effective vaccines for
the region it is critical to determine the serotype distribu-
tion in Egypt. However, a caveat in such assessment is that
isolates tested in the epidemiological studies were from
pneumococcal meningitis patients and therefore the iden-
tified serotype might not necessary represent all the sero-
types causing different forms of pneumococcal diseases as
certain serotypes may have a propensity to invade one
clinical site. Additionally, variation in the prevalent sero-
type amongst different studies conducted at different time
intervals were shown [7,10,11]. ES1998-2003  study con-
ducted to identify the serotype distribution addressed
only pneumococcal isolates obtained from CSF and there-
fore may not necessarily reflect isolates causing different
forms of pneumococcal diseases other than meningitis
[7]. A study conducted in Egypt in the late 1970s used
Quellung reaction, and identified type 1 as the most fre-
quently observed capsular type [10]. The study by Wasfy
et al., during ES1998-2003 reported the major serotypes {6B,
1, 19A, 23F, 6A} from CSF specimens of patients with
meningitis [7]. ES1998-2004 study by Afifi et al., confirmed
these finding, the study was conducted during the same
time period, and found the same predominant serotypes
in Egyptian patients [2]. Additionally 50% of multidrug
resistant isolates were characteristic of serotypes 23F, 6B
and 6A [2]. These serotypes are inadequately represented
in the current 7- (4, 6B, 9V, 14, 18C, 19F, 23F) and 11-
valent vaccine (contain four additional serotypes 1, 5, 3
and 7F) and therefore non of the current vaccines are used
in Egypt [2,7]. The predominant serotypes reveal
enhanced penicillin resistance when compared with other
serotypes. Interestingly, Guirguis et al., reported in 1990
that serotypes 1, 6A, 9L, 12A, 19A and 29 are the most fre-
quent serotypes identified in the study [11]. These studies
impose the importance and urgency to periodically collect
and analyze more data on the current predominant sero-
types present in Egypt [2]. This will aid in effective treat-
ment strategies, effective vaccine administration and
effective means to synthesize new effective vaccines for the
region.
Neisseria meningitidis
Neisseria meningitidis was for long reported as the leading
cause for bacterial meningitis in Egypt based on studies
conducted between 1965-1989 [3,5,13,23], recently it was
described as the second or third leading cause after S.
pneumoniae  [1,2,4]. Egypt has experienced several out-
breaks caused by meningococcal meningitis serogroup A.
During the period from 1966-1989 the country experi-
enced 3 outbreaks with a periodicity ranging from 6-8
years [23].
Gradual decrease in the prevalence of Meningococcal meningitis
Meningitis caused by Neisseria meningitidis is referred to as
meningococcal meningitis. In early studies from 1965-
1968 meningococcus was responsible for more than half
(56%) of the cases of bacterial meningitis patients (figure
2). The most affected age group was between 5-15 and the
highest mortality cases were reported in ages less than one
year. During this 4 years study there was a continuous rise
in death rate, which was explained by the development of
meningococcal strains resistant to sulpha [5]. Further
studies confirmed the prevalence of N. meningitidis as the
leading cause of bacterial meningitis [3,6,13,23].
N. meningitidis possessed a pattern in the occurrence of
outbreaks "cyclic nature"; a gradual increase in the
number of meningococcal cases every 6-8 years [3,23].
Serogroups A, B, and C were all reported however group A
constituted the majority of cases [3,13,14,23]. Most cases
occurred during winter months (Jan to Apr) in patients
between the ages of 5 and 14. Serogroup A had the least
mortality rate compared to serogroups B and C. Mortality
was highest in patients less than 1 year and more than 24
years [3]. During the last 2 years of ES1966-1989 an observed
change in the clinical presentation of patients with
meningococcal meningitis was reported where the onset
of the disease was more acute and the course was more
severe. Petechial rash was more common in the last years
with a higher percentage of mortality occurring in patients
developing the skin rash [3,23].
ES1977-1978 studied 1627 suspected meningitis cases and
performed CSF analysis; 5.5% of the total suspected cases
and 25.4% of the 350 culture-positive meningitis cases
were caused by N. meningitidis. This was reported as the
second most common bacterial meningitis with a mortal-
ity rate of 21% [10]. This was the only study during this
period that identified serotype C as the predominant sero-
group followed by B then A. Most cases occurred from
November to April affecting mainly infants and children.
Meningococcal meningitis cases had the lowest overall
mortality when compared with other bacterial meningitis
infections, yet its mortality rate was higher compared to
previous studies [10] possibly due to the prevalence of
serotype C [3,10].
Later studies showed a decline in N. meningitidis
[1,2,4,21] and a different dominating serotype. In a study
on 2047 children less than 6 years in Egypt ES1998-2000, N.Annals of Clinical Microbiology and Antimicrobials 2009, 8:26 http://www.ann-clinmicrob.com/content/8/1/26
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meningitidis was reported to be responsible for 13% of the
228 bacterial meningitis cases with 23% case fatality. This
study reported serogroup B being more common than
serogroup A, however, it is worth noting that this was
based on 8 isolates tested [4]. A Laboratory-based surveil-
lance of patients with bacterial meningitis was conducted
in 14 hospitals from 1998-2004 to determine the etiology
and the antimicrobial susceptibility of meningitis patho-
gens. N. meningitidis was responsible for 17% of the 843
cultured positive cases placing it third place after S. pneu-
moniae and H. influenzae. When PCR was performed on
culture negative isolates the N. meningitidis became the
second leading cause constituting 23% of the cases [2].
These studies show a gradual decrease in the prevalence of
Meningococcal meningitis and Figure 2 illustrates the per-
centage of meningiococcal meningitis cases from 1965 to
2004.
Antimicrobial resistance and treatment
Resistance of meningococcus to sulphonamides in Egypt
was detected in early studies in the 1960s [5,6] and table
2]. The data addressing the resistance profile for N. menin-
gitidis in Egypt is sparse owing to the absence of standard
criteria for the interpretation of the antibiotic sensitivity
data [2].
Youssef et al., reported that all N. meningitidis isolates were
susceptible to penicillin [4]. Afif et. al., reported high
resistance to trimethoprim/sulfamethoxazole, while inter-
mediate resistance was also reported with both penicillin
and trimethoprim/sulfamethoxazole in 34% of the iso-
lates. It was also reported that more than 40% of the iso-
lates showed intermediate resistance to either penicillin or
ampicillin [2]. Surveillance of antimicrobial susceptibility
testing carried by MOHP 1997-2000 on invasive patho-
Percentage of meningiococcal meningitis cases based on studies conducted over 39 years Figure 2
Percentage of meningiococcal meningitis cases based on studies conducted over 39 years. Nine different studies 
were conducted on patients diagnosed with meningitis due to N. meningitids from 1965-2004. Between 1966-1989, meningo-
coccal meningitis cases caused by serogroup A are only presented. In ES1965-1968conducted on 644 cases of ABM, it was 
reported that meningococcus was responsible for 56% of bacterial meningitis cases [5]. In ES1966-1968on 187 patients, N. menin-
gitidis was responsible for 49% of 123 culture positive cases and again identified as the leading cause of bacterial meningitis [6]. 
The prospective study ES1966-1989 on 7,809 patients also reported that 54% of meningitis cases were caused by N. meningitidis 
[23]. A retrospective study ES1971-1975 done on 1,333 patients reported that 56% of the cases were due to N. meningitidis infec-
tion [3]. ES1971-1974, on 783 patients reported that 54.4% (426) of the meningitis cases were due to meningococcal infection 
[14]. ES1977-1978 on 1627 CSF specimen demonstrated that N. meningitidis was the second most common bacterial meningitis 
(25.4% of the 350 bacterial meningitis cases) [10]. In the ES1998-2000 on 2047 children less than 6 years, N. meningitidis was 
reported to be responsible for 13% of the 228 bacterial meningitis cases [4]. The ES2000 identified N. meningitidis as the second 
leading cause of bacterial meningitis in Egypt responsible for 30% of the 223 patients positive culture [1]. Prospective study 
ES2002-2003 on 310 children clinically diagnosed with meningitis detected N. meningitidis in 14.2% of the cases and documented it 
as the second leading cause [21]. ES1998-2004 placed N. meningitidis as the third cause of bacterial meningitis [2]. The asterisks 
represent epidemiological studies reporting an average during the entire period of the study.
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gens in Egypt reported that only 2% of isolates were resist-
ant to ceftriaxone [1]. Table 2 summarizes N. meningitidis
resistance to penicillin, ampicillin, chloramphenicol,
ceftriaxone, tetracycline, and trimethoprim/sulfamethox-
azole from 1998-2004, note that N. meningitidis were iso-
lated from CSF and/or blood.
Shift in the serogroups distribution following the implementation of 
the bivalent A/C vaccine
Early studies indicated that the major serogroup in Egypt
was serogroup A, which accounts for 95% of the cases
[3,13,14,17]. The observed cyclic nature of the disease
reported in the ES1966-1989 study permitted the design of
the first successful serogroup A meningococcal polysac-
charide vaccine trial in Egypt [3,18]. The results of the first
trial conducted in ES1971-1972 indicated that the vaccine
conferred significant protection where it was able to pro-
duce high degree of immunity for the following three
years when compared to the control cases [18]. In 1977
the second clinical assessment for serogroup A meningo-
coccal vaccine was carried out in Alexandria on school
children to assess the effectiveness of the vaccine, it was
found to be effective for one year following immuniza-
tion. There was an observed decrease in protection after
the first year, which was inconsistent with what was
observed during the first trial [16]. A study conducted dur-
ing the same period 1971-1972 by Sippel et al., revealed a
high number of carriers of group B and C, anticipating a
possible change in the epidemiological pattern of the
serogroups in Egypt [15]. A study by Guirguis et al., ES1977-
1978 reported an unusual pattern in serogroups where C
was the predominant followed by B then A [10].
In 1992 the MOHP initiated a school based vaccination
program with the bivalent A/C capsular polysaccharide
vaccine. The vaccine was taken at age of 6 years followed
by a second dose 3 years later. A retrospective review by
Nakhla et al., to understand the change in epidemiology
of meningococcal serogroups after the introduction of the
bivalent vaccine indicated a significant decrease in menin-
gococcal cases following the implementation of the
school-based vaccination program [17]. It is worth noting
that the expected outbreak in 1996 has actually never
occurred and it was reported that there is a decline in the
incidence of meningococcal meningitis cases [23,24].
A more recent study ES1998-2000 reported a higher number
of serogroup B than A [4]. Another study by Afifi et al.,
reported out of 135 isolates of N. meningitidis 51% were
group B, 35% group A, 4% group W-135 and 2%
belonged to group D and Y [2]. The project conducted by
MOHP in 2000 in addressing the communicable diseases
in Egypt reported that meningococci were compromised
of 54.5% of serogroup B, 31.8% group A, 4.5% group
W135, 2.3% group Y [1]. This shift in the serogroups was
observed after the implementation of the bivalent A/C
vaccine by MOHP implying the significant impact that the
vaccine had on the epidemiology of the disease [17].
Haemophilus influenzae
Sparse epidemiology studies are available addressing the
pathogenicity of H. influenzae. It was less implicated in
meningitis in earlier studies conducted in Egypt [3,13], yet
recently it was reported in limited studies to be one of the
leading causes of bacterial meningitis in Egyptian children
[1,2,4]. It is difficult to estimate the incidence of H. influ-
enzae meningitis in Egypt due to absence of population
based analysis and limited surveillance studies [4]. One
study ES1998-2004, defined H. influenzae serotype b as the
main cause of pneumonia in children below 5 year [2].
H. influenzae the leading cause of meningitis in very young children
A prospective study ES1966-1989 on 7,809 patients admitted
to the Abbassia Fever hospital, reported H. influenzae to be
the cause of meningitis in 322 of the patients (4.1%) who
had a mean age of 2.5 years; it is worth noting that most
Table 2: Antibiotic resistant N. meningitidis isolates.
N. meningitidis PEN AMP CHL CRO SXT Number of isolates tested
ES 1998-2000
[4]
R = 0% NA NA NA NA -8
-CSF
ES 1997-2000
[1]
NA I = 84% I = 0% I = 17% NA -48
R = 2% R = 0% R = 2% -CSF and blood
ES 1998-2004
[2]
R = 1% R = 5% NA NA R = 86 -68
% -CSF
The percentage of non-susceptible N. meningitidis isolates to five conventional antibiotics to N. meningitidis isolated from CSF and/or blood in three 
studies conducted from1998-2004.
The antibiotic abbreviations: PEN, penicillin; AMP, ampicillin; CHL, chloramphenicol; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim/
sulfamethoxazole; and NA refers to data not available.
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of the cases (76%) were patients less than one year. Most
cases occurred in winter months with a gradual increase in
the number of cases from one year to the next. The mor-
tality rate of H. influenzae was 39% [3,23]. In the two-year
study ES1966-1968 conducted at AFH on 187 patients, H.
influenzae was responsible for 12% of 123 culture-positive
cases identified [6].
A retrospective review of 1,333 patients with acute bacte-
rial meningitis admitted to the Abbassia Fever hospital
from 1 January 1971 to 31 December 1975 reported only
2.6% (35 cases) of the cases were due to infection with H.
influenzae, and most cases were children less than one year
(57%) with 27% case fatality [13].
Following this another two year study 1977-1978 at
Embaba and Abbasisa Fever Hospitals H. influenzae was
reported to be responsible for only 2.6% of the total 1627
CSF specimens and 12% of the 350 culture positive iso-
lates. In contrast to the low frequency of H. influenzae
infection the mortality rate was high (57%) among very
young children with type b [10].
Surveillance for patients with bacterial meningitis in 12
hospitals in Egypt between May 1998 and December 2000
was conducted to determine the etiology of the disease in
children less than 6 years. Of 228 patients that had cul-
tured- confirmed disease 39% showed H. influenzae as the
leading cause of the disease with 81% of the H. influenzae
case-patients were less than 12 months. The mortality rate
was 27% with serotype b being responsible for most of the
cases [4]. As a part of a project performed by the MOHP in
Egypt, it was reported that H. influenzae was responsible
for 14.3% of 223 patients having bacterial meningitis [1].
A prospective study ES2002-2003 conducted in Alexandria
fever hospital on 310 children clinically diagnosed with
meningitis, detected 21% of the cases were caused by H.
influenzae, again the leading cause of acute bacterial men-
ingitis in this study [21]. In a laboratory-based surveil-
lance ES1998-2004  carried out to identify the etiological
agent of bacterial meningitis, H. influenzae was found to
be the second leading cause following S. pneumoniae
responsible for 20% of the 843 cases of culture positive
patients. Among children less than 5 year H. influenzae
was the most common bacteria isolated. The mean age
was 7 months with a case fatality ratio of 25% [2]. Figure
3 illustrates the prevalence and trends of H. influenzae in
bacterial meningitis cases.
Antibiotic resistance and treatment
The study by Ostroff et. al., is considered the first study in
Egypt to identify the resistant pattern of H. influenzae.
Percentage of Meningitis Cases Caused by Haemophilus influenzae Figure 3
Percentage of Meningitis Cases Caused by Haemophilus influenzae. Eight different studies were conducted on patients 
diagnosed with meningitis caused by H. influenzae from 1965-2004. ES1966-1989 reported H. influenzae to be the cause of menin-
gitis in 4.1% of 7,809 patients [3]. In ES1966-1968 H. influenzae was responsible for 12% of 123 culture-positive cases [6]. ES1971-
1975 study of 1,333 patients with ABM reported only 2.6% of meningitis cases were due to infection with H. influenzae [13]. 
ES1977-1978 H. influenzae was reported to be responsible for 2.6% of the total 1627 CSF specimens and 12% of the 350 culture-
positive isolates [10]. ES1998-2000 on children less than 6 years, 39% of the 228 patients' cultured- confirmed disease 39% showed 
H. influenzae [4]. ES2000 revealed that H. influenzae was responsible for 14.3% of 223 positive bacterial culture meningitis cases 
[1]. ES2002-2003 on 310 children clinically diagnosed with meningitis identified 202 cases as ABM where 21% of the ABM cases 
were caused by H. influenzae [21]. ES1998-2004 H. influenzae was responsible for 20% of the 843 cases of culture-positive patients 
[2]. The asterisks represent epidemiological studies reporting an average during the entire period of the study.
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Although no resistance was detected in the isolates
obtained from the blood, yet strains obtained from 347
nasopharynx isolates conferred certain level of resistance
for the tested antibiotics. It was reported that 1.4% and
5.6% of the isolates conferred intermediate and full resist-
ance to ampicillin respectively, 10.8% and 4.3% conferred
intermediate and full resistance to SXT respectively, 1%
and 10% conferred intermediate and full resistance to
chloramphenicol respectively (table 3). The yield of iso-
lates from blood as indicated in table 3 was very low (only
6) to be able to draw definitive conclusions regarding the
resistance pattern [8].
The Surveillance conducted by MOHP reported increase
in the resistance pattern from the above study. It also
reported multi-drug resistance (TET, SXT, and CHL) in
29.6% of the isolates, in addition to positive β-lactamase
activity [1].
Youssef et. al., demonstrated that less than 50% of H.
influenzae  isolates were susceptible to chloramphenicol
and ampicillin while all isolates were susceptible to third
generation cephalosporins; ceftriaxone. It was reported
that higher mortality rate were found in patients with H.
influenzae resistant isolates to AMP and CHL [4]. In the
laboratory-based surveillance ES1998-2004 conducted in a
network of 14 hospitals 45% ampicillin resistant isolates
were reported, 37% of which demonstrated beta-lacta-
mase production (Table 3) [2].
Serotype distribution and vaccination
Since earlier studies H. influenzae serotype b was predom-
inantly reported among the few reported cases. Guirguis et
al., reported that all H. influenzae isolates were serotype b;
out of 47 H. influenzae isolates 30 were tested and all of
them were type b [4]. The finding that the majority of H.
influenzae isolates were type b [20] and a common cause
of acute lower respiratory infection allowed the introduc-
tion of Hib vaccine by the MOHP in the EPI (Expanded
Program on Immunization) [1,4].
Concluding Remarks
The dominating causative agent for bacterial meningitis
has changed over the forty years period studied. Studies
have demonstrated that Pneumococcal meningitis is cur-
rently the leading cause of meningitis in Egypt. Studies on
the prevalent bacterium in different age group shows that
H. influenzae is the leading cause of meningitis in very
young children. The serotype prevalence of some bacterial
species were altered over the years changing the mortality
rate of the disease. Several bacteria have developed anti-
microbial resistance to conventional antibiotic regimes
and emerging multidrug resistance strains. The referenced
studies have provided the platform for assessing the prev-
alence and antimicrobial resistance pattern of bacterial
meningitis in Egypt. However, this also iterates the need
for periodic and continual surveillance to guide the
empirical treatment of such diseases.
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Table 3: Antibiotic resistant H. influenzae isolates.
H. influenzae PEN AMP CHL CRO TET SXT -Number of isolates tested
-Source
ES 1991-1993
[8]
NA I = 0% I = 0% NA NA I = 0% -6
R = 0% R = 0% R = 0% -Blood
ES 1997-2000
[1]
NA I = 16% I = 24% I = 0% NA NA -75
R = 30% R = 60% R = 6% -CSF
ES 1998-2000
[4]
I = 0% I = 16% I = 20% I = 0% I = 5% I = 5% -47
R = 45% R = 63% R = 67% R = 0% R = 81% R = 45% -CSF
ES 1998-2004
[2]
NA R = 45% R = 37% NA NA R = 40% -119
-CSF
The percentage of non-susceptible H. influenzae isolates to seven conventional antibiotics to H. influenzae isolated from CSF and/or blood in three 
studies conducted from1991-2004.
The antibiotic abbreviations: PEN, penicillin; AMP, ampicillin; CHL, chloramphenicol; CRO, ceftriaxone; TET, tetracycline; SXT, trimethoprim/
sulfamethoxazole; ERY, erythromycin and NA refers to data not available.
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